OSE Immuno stock drops 37% over three months and slips below its support level
The Nantes biotech company is declining during the session, following its first phase 2 results in lung cancer. The stock is trading below its three moving averages, in a Paris market oriented downward.
A stock below its three moving averages, near its support level
OSE Immuno stock loses 2.69% to €2.02, while the CAC 40 falls 0.69% and the SBF 120 drops 0.72%. The price is 2.5% below its support threshold of €2.04, following a decline of 4.89% over the week and 37.18% over three months. The gap with the MA20 (€2.22) is 8.8%, while that with the MA200 (€3.62) reaches 44%.
The RSI at 34 remains close to the oversold zone, without entering it. In the session ranking, the stock declines 2.69% within the CAC All Shares.
Positive phase 2 data, but more frequent adverse effects
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
OSE Immunotherapeutics unveiled on October 19 the first results of the Combi-TED trial, selected for an oral presentation at the ESMO congress. The two combinations associating Tedopi with docetaxel or nivolumab achieved the one-year overall survival criterion, with rates of 47% and 46%, respectively, compared to 29% for docetaxel alone. The press release also mentions higher rates of adverse events in the combined arms than in the reference arm.
On September 28, the company indicated it had liquidity funded until the end of 2026 and was continuing discussions with investors in the United States and Europe. Its third-quarter cash position will be published on October 27.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Guidance from the release
La Société poursuit activement ses interactions avec les investisseurs institutionnels aux États-Unis et en Europe afin d'étendre son horizon de financement au-delà des points d'inflexion de valeur à venir
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
